ESR1 and breast cancer: Galloflavin, a derivative of gallic acid, is a significant antiglycolytic drug that inhibits both LDHA and LDHB in TNBC and estrogen receptor-positive/progesterone receptor-positive (ER +/PR +) breast cancer [166].